“High Score” in a Patient with Tophaceous Gout
Rech J,,Manger B,Schett G,Cavallaro A,,,,,,,
DOI: https://doi.org/10.26420/austinjradiol.2021.1122
2021-02-26
Austin Journal of Radiology
Abstract:A 71-year old semi-somnolent patient with 3-vessel khk, chronic heart failure III°, COPD, obesity, diabetes type II, renal insufficiency, several amputated fingers and toes during a 48-year history of chronic gout was referred to our rheumatology clinic due to suspected superinfected wound of ulcerated gouty tophi. At admission the patient was on torasemid 15mg/die, febuxostat 80mg/die, ASS 100mg/ die, sitagliptin 50mg/die since years. Laboratory studies were notable for serum uric acid level of 7.7mg per deciliter, C-reactive protein 288.5mg per liter; creatinine clearance rate of 56 ml per minute per 1.73 m2 of body-surface area. We adapted the dosage of febuxostat to 120mg/die and added kineret for 3 days, followed by canakinumab 150mg s.c. every 12 weeks. Dual energy-CT (Figure 1) of both elbows, hands, chest, knees and feets was performed, revealing a high score of 1014, 4cm3 tophi volume = 2316, 5mg weight (C5H3N4O3Na; molecular weight, 190.09) [1]. To our knowledge this amount of tophi volume, measured by DECT, has never been reported in the literature before. By adding lesinurad 200mg/d to febuxostat 120mg/ die and canakinumab 150mg every 12 weeks uric acid level and C-reactive protein decreased to 5.1mg per deciliter and 24mg per liter respectively with reduction of clinical flares over the next 9 months.
English Else